RAS Amplification as a Negative Predictor of Benefit from Anti‐EGFR–Containing Therapy Regimens in Metastatic Colorectal Cancer

BACKGROUND: RAS short variant (SV) mutations in colorectal cancer (CRC) are associated with lack of benefit from epidermal growth factor receptor (EGFR) monoclonal antibody (EGFRmAb). However, the clinical implications for RAS amplification (RASa) as a biomarker for anti‐EGFR therapy in CRC remain i...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Schrock, Alexa B., Lee, Jessica K., Sandhu, Jaideep, Madison, Russell, Cho‐Phan, Cheryl, Snider, Jeremy W., Castellanos, Emily, Venstrom, Jeffrey M., Fakih, Marwan
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2021
Assuntos:
Gastrointestinal Cancer
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8176984/
https://ncbi.nlm.nih.gov/pubmed/33465286
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13679
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados